Welcome to our dedicated page for Ocular Therapeut news (Ticker: OCUL), a resource for investors and traders seeking the latest updates and insights on Ocular Therapeut stock.
Ocular Therapeutix, Inc. (NASDAQ: OCUL) generates frequent news as an ophthalmology-focused biopharmaceutical company advancing late-stage retinal programs and a commercial eye-care product. Its press releases highlight progress across the AXPAXLI (OTX-TKI) clinical programs in wet age-related macular degeneration (wet AMD) and non-proliferative diabetic retinopathy (NPDR), as well as updates related to DEXTENZA, financings, and corporate events.
News coverage for OCUL commonly includes clinical milestones such as target randomization in the SOL-R Phase 3 wet AMD trial, completion of randomization in SOL-1, and the initiation or advancement of the HELIOS Phase 3 registrational program in NPDR. The company also issues announcements about regulatory strategy, including Special Protocol Assessment (SPA) agreements with the U.S. Food and Drug Administration for SOL-1 and HELIOS-2 and plans to leverage the 505(b)(2) pathway for AXPAXLI in wet AMD.
Investors following OCUL news will see regular business and capital markets updates, such as underwritten equity offerings, cash runway disclosures, and inducement equity grants under Nasdaq Listing Rule 5635(c)(4). The company also reports quarterly financial results and business highlights, describing clinical execution, trial timelines, and planned extension studies like SOL-X for long-term evaluation of AXPAXLI in wet AMD.
In addition, Ocular Therapeutix announces participation in scientific and investor conferences, where it presents data from earlier-stage trials (for example, HELIOS Phase 1 results in NPDR) and discusses its strategy to "redefine the retina experience." For a consolidated view of these developments, the OCUL news page on Stock Titan brings together clinical, regulatory, financial, and corporate communications so readers can track how trial outcomes, regulatory interactions, and financing activities may shape the company’s ophthalmic pipeline and commercial portfolio over time.
Ocular Therapeutix (NASDAQ: OCUL) will participate in multiple scientific conferences in October 2025 to present clinical and company data on retina therapies.
Key appearances: American Academy of Optometry (Boston, Oct 8–11) — poster on one‑year HELIOS Phase 1 OTX‑TKI safety and efficacy on Oct 9, 4:30–6:30 PM ET by Trung Tran; Eyecelerator @ AAO (Orlando, Oct 16) — company showcase by Peter K. Kaiser, MD on Oct 16, 1:15–2:45 PM ET; American Academy of Ophthalmology (Orlando, Oct 18–20) — on‑demand poster on macular fluid and vascular leakage after a single axitinib intravitreal hydrogel, presented by Margaret Chang, MD, MS. Exact times may change.
Ocular Therapeutix (NASDAQ: OCUL) has announced the pricing of an underwritten public offering of 37,909,018 shares of common stock at $12.53 per share, aiming to raise approximately $475.0 million in gross proceeds.
The proceeds will fund several key initiatives, including the open-label extension study for AXPAXLI™ in wet AMD patients, Phase 3 clinical trials for non-proliferative diabetic retinopathy treatment, infrastructure investments, manufacturing support, and pre-commercialization activities for AXPAXLI. The offering is expected to close around October 1, 2025.
BofA Securities, TD Cowen, and Piper Sandler & Co. are serving as joint book-running managers, with Baird and Raymond James as lead managers, and Citizens Capital Markets and H.C. Wainwright & Co. as co-managers.
Ocular Therapeutix (NASDAQ:OCUL) is hosting an Investor Day to showcase progress in their retinal disease programs. The company's lead candidate AXPAXLI™ is advancing in two key areas:
In wet AMD, the SOL-1 superiority trial shows >95% patient retention with topline data expected in Q1 2026, while the SOL-R non-inferiority trial is on track for H1 2027 results. Both trials could support the first superiority label versus aflibercept.
For diabetic retinopathy, Ocular announced two new Phase 3 trials: HELIOS-2 and HELIOS-3, featuring a novel FDA-aligned ordinal endpoint measuring both disease improvement and prevention of worsening. HELIOS-2 will evaluate 432 patients comparing AXPAXLI to ranibizumab, while HELIOS-3 will study 930 patients across three treatment arms.
Ocular Therapeutix (NASDAQ:OCUL) will host an Investor Day on September 30, 2025 in New York City, featuring presentations from senior leadership and global retina experts. The event will focus on the company's AXPAXLI™ program for wet age-related macular degeneration (wet AMD), including the SOL trials and potential superiority label.
Distinguished Key Opinion Leaders participating include Dr. Arshad M. Khanani, Professor Adnan Tufail, Dr. Eleonora Lad, and Dr. Patricio G. Schlottmann. The event will also cover clinical strategies for non-proliferative diabetic retinopathy (NPDR), diabetic macular edema (DME), and AXPAXLI's global commercial opportunities across retinal indications.
Ocular Therapeutix (NASDAQ: OCUL) has announced its participation in multiple investor and scientific conferences during September 2025. The company's leadership will participate in two major investor conferences: the Morgan Stanley Global Healthcare Conference on September 8 and the Baird Global Healthcare Conference on September 9, both featuring fireside chats with CEO Pravin U. Dugel.
Additionally, the company will have a significant presence at several scientific conferences in Paris, including EURETINA Innovation Spotlight, Ophthalmology Futures Forums, and the 25th EURETINA Congress. Key presentations will focus on the company's OTX-TKI treatment for diabetic retinopathy, featuring data from the HELIOS Clinical Trial. The scientific program will conclude with a presentation at The Retina Society's 58th Annual Scientific Meeting in Chicago.
Ocular Therapeutix (NASDAQ: OCUL) has secured FDA agreement under Special Protocol Assessment (SPA) for a registrational trial of AXPAXLI in non-proliferative diabetic retinopathy (NPDR). The agreement provides a clear regulatory pathway for AXPAXLI's development in diabetic eye disease.
Phase 1 HELIOS trial results showed promising outcomes: no NPDR patients receiving AXPAXLI experienced disease progression or vision-threatening complications at 48 weeks, compared to 25% disease worsening and 40% vision-threatening complications in the control group. The treatment, designed for annual dosing, targets a significant market with nearly 9 million Americans affected by diabetic retinopathy.
The company will present detailed clinical trial design, timing, and development strategy for NPDR and diabetic macular edema (DME) at its upcoming Investor Day on September 30, 2025.
Ocular Therapeutix (NASDAQ:OCUL) reported Q2 2025 financial results and business updates, highlighting significant progress in its retinal disease programs. The company reported a cash balance of $391.1 million as of June 30, 2025, bolstered by a $97 million raise through its ATM facility, extending runway into 2028.
Key financial metrics include total net revenue of $13.5 million (18.1% decrease YoY) and a net loss of $67.8 million ($0.39 per share). The company's flagship AXPAXLI™ trials for wet AMD are progressing well, with SOL-1 topline data expected in Q1 2026 and SOL-R data in 1H 2027. AXPAXLI aims to be the first product with a superiority label in wet AMD, potentially allowing dosing every 6-12 months.
Ocular Therapeutix (NASDAQ:OCUL), a biopharmaceutical company focused on retina treatments, has scheduled its Q2 2025 earnings conference call for Tuesday, August 5, 2025, at 8:00 AM ET. The company will discuss its business progress and financial results for the quarter ended June 30, 2025.
The call will be accessible via U.S. dial-in (1-877-407-9039), international dial-in (1-201-689-8470), and webcast. A replay will be available on the company's Investor Relations page for at least 30 days following the presentation.
Ocular Therapeutix (NASDAQ: OCUL) announced its participation in three major scientific conferences in July and August 2025. The company will present at the 8th Annual OIS Retina Innovation Summit, ASRS 2025 43rd Annual Scientific Meeting in Long Beach, CA, and Women in Ophthalmology (WIO 2025) in Amelia Island, Florida.
Key presentations will focus on the company's OTX-TKI (axitinib hydrogel) treatment for diabetic retinopathy, including data on retinal leakage assessment and macular fluid outcomes. Notable speakers include Chief Strategy Officer Sanjay Nayak, Chief Development Officer Peter K. Kaiser, and other medical experts.
Ocular Therapeutix (NASDAQ: OCUL) has unveiled new corporate branding to reflect its transformation into a retina-focused company. The rebranding features a new logo with a circular "O" representing the eye and retina, along with a full-spectrum color palette symbolizing human vision.
The company's primary focus is on disrupting retinal disease treatment, particularly wet age-related macular degeneration (AMD), which affects 1.8 million people in the U.S. Their investigational therapy, AXPAXLI™ (OTX-TKI), aims to address the limitations of current treatments that require up to 12 injections yearly and often lead to complications like fibrosis and atrophy.
FAQ
What is the current stock price of Ocular Therapeut (OCUL)?
What is the market cap of Ocular Therapeut (OCUL)?
